Journal
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
Volume 39, Issue -, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmcl.2021.127854
Keywords
P300; CBP; Histone acetyltransferase; Spirohydantoin
Categories
Funding
- NIH [R35 GM118090, GM62437]
- DOE Office of Science [DEAC0206CH11357]
- Industrial Macromolecular Crystallography Association
- HauptmanWoodward Medical Research Institute
Ask authors/readers for more resources
p300 and CBP play essential roles in cellular processes and dysregulation of their histone acetyltransferase activity is linked to various human diseases. The novel drug-like compound 21 is a selective orally bioavailable inhibitor of p300/CBP histone acetyltransferase, more potent than A-485 and lacking off-target inhibition of dopamine and serotonin transporters.
p300 and CREB-binding protein (CBP) are essential for a multitude of cellular processes. Dysregulation of p300/ CBP histone acetyltransferase activity is linked to a broad spectrum of human diseases including cancers. A novel drug-like spirohydantoin (21) has been discovered as a selective orally bioavailable inhibitor of p300/CBP histone acetyltransferase. Lead compound 21 is more potent than the first-in-class lead A-485 in both enzymatic and cellular assays and lacks the off-target inhibition of dopamine and serotonin transporters, that was observed with A-485.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available